Thomas Buchholz
Direktor/Vorstandsmitglied bei Nucleix Ltd.
Profil
Thomas Buchholz is currently the Director at Nucleix Ltd.
He completed his undergraduate degree at Bucknell University and his doctorate at Tufts University School of Medicine.
Aktive Positionen von Thomas Buchholz
| Unternehmen | Position | Beginn |
|---|---|---|
Nucleix Ltd.
 Nucleix Ltd. Medical/Nursing ServicesHealth Services Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel. | Direktor/Vorstandsmitglied | 11.05.2020 |
Ausbildung von Thomas Buchholz
| Tufts University School of Medicine | Doctorate Degree |
| Bucknell University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Nucleix Ltd.
Nucleix Ltd. Medical/Nursing ServicesHealth Services Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel. | Health Services |
